Thrombogenics NV (Euronext Brussels: THR), a Belgium based biotechnology company, announced January 14th as the launch date for their new treatment for symptomatic vitreomacular adhesion (VMA). Dr. Patrik De Haes, Chief Executive Officer of Thrombogenics, presented the company’s launch plans on January 9th during the 31st Annual J.P. Morgan Healthcare Conference held San Francisco, USA. The new treatment, branded as “Jetrea”, is an intravitreal injection of a proteolytic enzyme (ocriplasmin) that cleaves fibronectin, laminin and collagen, understood to play an important role in vitreomacular adhesion. The drug is heralded as the first pharmacological agent to be approved for VMA. The new drug will aim to replace vitrectomy as the first-line treatment for VMA, related traction and macular hole and will be priced at US $3,950 per single-use glass vial.